Douglas B. Johnson, M.D., M.S.C.I.
Biomarkers for immune and targeted therapeutics; Developing clinical trials for melanoma patients
Dr. Doug Johnson recently joined the Vanderbilt faculty in the Division of Hematology/Oncology with a focus on melanoma and a broader interest in molecular profiling, targeted therapy, and immune therapy across cancer types. After growing up in San Antonio, TX, he completed medical school at the University of Alabama at Birmingham, residency at Duke University, and, more recently, a fellowship and the MSCI program at Vanderbilt. He is now on the physician-scientist track performing clinical and translational research. Dr. Johnson's primary scientific interests are in developing and understanding biomarkers for immune and targeted therapeutics and developing clinical trials for melanoma patients.
Dr. Johnson leads the melanoma clinical research program at Vanderbilt. His research interests cover a wide range of developing new immune and targeted therapies for melanoma, and in using existing treatments in the most effective ways. Specifically, he is exploring ways to profile cancers to predict which patients will benefit from immune therapies, and has published numerous papers in this area. He is also focused on understanding the effectiveness and toxicities of immune therapies in high risk patients, including those with autoimmune disorders, advanced age, or organ dysfunction. Dr. Johnson is the lead investigator on numerous clinical trials at Vanderbilt.